PD07.04. Prognosis of Patients With Esophageal Squamous Cell Carcinoma Achieved Pathological Complete Regression After Neoadjuvant Immunochemotherapy

Clicks: 22
ID: 325906
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #67 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Pathological complete response (pCR) is an important outcome following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). However, the long-term prognosis and predictive factors for recurrence in patients who achieve pCR remain poorly characterized. Methods This retrospective study analyzed 154 ESCC patients who achieved pCR after neoadjuvant platinum-based chemotherapy combined with immune checkpoint inhibitors, followed by esophagectomy at our center (Jan 2020–Jun 2025). Preoperative clinical staging and postoperative pathological assessment were standardized. The primary endpoints were 3-year disease-free survival (DFS) and overall survival (OS). Survival curves were generated using the Kaplan-Meier method with log-rank test for comparison. Prognostic factors were identified via Cox proportional hazards regression. Results After a median follow-up of 25 months, the 3-year DFS and OS rates were 72% and 88%, respectively. Multivariate analysis identified ≥3 treatment cycles (HR 6.598, 95% CI 1.640–26.549, P=0.008), treatment-to-surgery interval <5 weeks (HR 4.374, 95% CI 1.070–17.869, P=0.040), and BMI <23.9 kg/m2 (HR 5.083, 95% CI 1.052–24.566, P=0.043) as independent risk factors for reduced DFS; higher clinical T-stage also correlated (P=0.019). For OS, older age (HR 1.234 per year, 95% CI 1.074–1.417, P=0.003) and low BMI (HR 62.560, 95% CI 2.892–1353.481, P=0.008) were significant, with higher cT-stage showing probable association (P=0.029). Postoperative adjuvant therapy did not improve outcomes. Conclusion Achieving pCR does not guarantee cure. Distinct risk profiles emerge: factors like extensive neoadjuvant cycles, short treatment-to-surgery interval, low BMI, and advanced cT stage primarily signal recurrence risk, while older age and low BMI independently predict worse overall survival. Critically, adjuvant therapy offered no survival benefit. These findings call for risk-stratified postoperative surveillance over routine adjuvant therapy in pCR patients.
Reference Key
openalex_W7203973595 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zongpu Zhang, Bin Li, Haiquan Chen
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.126
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.126/70760592/doag077.126.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.